IS7482A - Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf - Google Patents
Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyfInfo
- Publication number
- IS7482A IS7482A IS7482A IS7482A IS7482A IS 7482 A IS7482 A IS 7482A IS 7482 A IS7482 A IS 7482A IS 7482 A IS7482 A IS 7482A IS 7482 A IS7482 A IS 7482A
- Authority
- IS
- Iceland
- Prior art keywords
- alpha2
- strong
- adrenoceptor antagonists
- multicyclic compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 title 1
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Secondary Cells (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36934702P | 2002-04-03 | 2002-04-03 | |
| FI20020642A FI20020642A0 (fi) | 2002-04-03 | 2002-04-03 | Polysykliset yhdisteet tehokkaina alfa2-adrenoseptoriantagonisteina |
| PCT/FI2003/000255 WO2003082866A1 (en) | 2002-04-03 | 2003-04-03 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7482A true IS7482A (is) | 2004-10-01 |
Family
ID=28676457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7482A IS7482A (is) | 2002-04-03 | 2004-10-01 | Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7592350B2 (is) |
| EP (1) | EP1490361B1 (is) |
| JP (1) | JP2005522468A (is) |
| CN (1) | CN100372845C (is) |
| AT (1) | ATE374773T1 (is) |
| AU (1) | AU2003216760A1 (is) |
| BR (1) | BR0309028A (is) |
| CA (1) | CA2480695A1 (is) |
| DE (1) | DE60316672T2 (is) |
| EA (1) | EA008537B1 (is) |
| HR (1) | HRP20041026A2 (is) |
| HU (1) | HUP0500201A2 (is) |
| IL (1) | IL164203A0 (is) |
| IS (1) | IS7482A (is) |
| MX (1) | MXPA04009601A (is) |
| NZ (1) | NZ535950A (is) |
| PL (1) | PL372657A1 (is) |
| RS (1) | RS87204A (is) |
| WO (1) | WO2003082866A1 (is) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物 |
| US8906647B2 (en) | 2008-02-21 | 2014-12-09 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome P450 |
| TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
| CN102724875B (zh) | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚化合物及其使用方法 |
| GB2503187A (en) * | 2011-09-15 | 2013-12-25 | Univ Sussex | Composition for use in the treatment of neurodevelopmental disorders |
| AR104882A1 (es) | 2015-06-05 | 2017-08-23 | Orion Corp | DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C |
| CN107286158A (zh) * | 2016-03-30 | 2017-10-24 | 中国科学院上海药物研究所 | 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 |
| KR20190020343A (ko) | 2016-06-29 | 2019-02-28 | 오리온 코포레이션 | 벤조디옥산 유도체 및 이의 약제학적 용도 |
| WO2019191776A1 (en) | 2018-03-31 | 2019-10-03 | Hall John L | Selective anti-cancer agent effective for prevention and treatment |
| CN110922412A (zh) * | 2018-09-20 | 2020-03-27 | 复旦大学 | 具有抗精神病作用药物化合物的不对称合成方法 |
| IT201800009072A1 (it) * | 2018-10-01 | 2020-04-01 | Universita' Degli Studi Di Cagliari | IL COMPOSTO (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a, 13,13a-DECAIDRO-3-METOSSI-12-(ETILSOLFONIL)-6H-ISOCHINO [2,1-g][1,6]NAFTIRIDINA PER L’USO NEL TRATTAMENTO DELLE PSICOSI |
| WO2020072675A1 (en) * | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| EP3965763A1 (en) | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Arylquinoziline derivatives as alpha2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea |
| CN111116578B (zh) * | 2019-12-26 | 2021-06-04 | 深圳市老年医学研究所 | 去亚甲基小檗碱的制备方法及其应用 |
| WO2022008426A1 (en) | 2020-07-06 | 2022-01-13 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
| CN112457314A (zh) * | 2020-11-19 | 2021-03-09 | 烟台大学 | 手性吲哚并吲哚里西啶类化合物及其制备方法 |
| CN116143783B (zh) * | 2021-11-23 | 2024-09-20 | 中国科学院大连化学物理研究所 | 一种单萜吲哚生物碱化合物及其制备和应用及药物 |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| CN118475347A (zh) | 2021-12-22 | 2024-08-09 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 |
| US20250074899A1 (en) | 2022-01-07 | 2025-03-06 | Bayer Aktiengesellschaft | A2-adrenoceptor subtype c antagonists for the treatment of sleep apnea |
| CA3248349A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-2-YLMETHYL)PIPERAZINE-1-YL DERIVATIVES FOR THE TREATMENT OF SLEEP APNEA |
| AR133983A1 (es) | 2023-09-28 | 2025-11-19 | Bayer Ag | Carboxamidas heterocíclicas sustituidas y su uso |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1209650A (fr) | 1957-09-12 | 1960-03-02 | Hoffmann La Roche | Procédé pour la préparation de dérivés d'indolo-quinolizines |
| GB844342A (en) | 1958-04-24 | 1960-08-10 | Roche Products Ltd | Novel quinolizine derivatives and a process for the manufacture thereof |
| GB983848A (en) | 1960-03-12 | 1965-02-17 | Philips Nv | Improvements in or relating to indoloquinolizine compounds |
| FR1524953A (fr) | 1962-03-26 | 1968-05-17 | Konink Pharmaceutische Fabrike | Procédé de préparation des dérivés de la quinolizine |
| GB1003645A (en) | 1962-10-09 | 1965-09-08 | Koninklijke Pharma Fab Nv | Indolo-indolizine compounds |
| US3203961A (en) * | 1963-03-21 | 1965-08-31 | Indolylethylpyrromdone compounds | |
| US3492303A (en) * | 1967-07-28 | 1970-01-27 | Warner Lambert Pharmaceutical | 1,2,3,4,4a,5,6,8,9,14,14b,14c-dodecahydrobenz(h)indolo(2,3-a)quinolizines |
| GB1435573A (en) | 1973-05-25 | 1976-05-12 | Wyeth John & Brother Ltd | Indoloquinolizines |
| HU170495B (is) * | 1974-05-07 | 1977-06-28 | ||
| US4044012A (en) * | 1974-05-07 | 1977-08-23 | Richter Gedeon Vegyeszeti Gyar Rt. | Indolo-quinolizidine derivatives |
| FR2478639A1 (fr) | 1980-03-20 | 1981-09-25 | Sanofi Sa | Nouveaux derives de l'indolizino (8,7-b) indole et intermediaires, leur procede de preparation et leur utilisation en therapeutique |
| GB2106909B (en) | 1981-10-07 | 1984-09-19 | Wyeth John & Brother Ltd | Benzoquinolizines |
| EP0089926A3 (de) | 1982-03-24 | 1984-05-16 | Ciba-Geigy Ag | Pharmazeutische Präparate enthaltend stickstoffhaltige Tetracyclen sowie neue Verbindungen dieser Art |
| HU188022B (en) * | 1983-06-29 | 1986-03-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for production of derivatives of indolo /2,3-g/cyylopent /a/ indolizin |
| GB2167408B (en) | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| HU194221B (en) * | 1985-04-19 | 1988-01-28 | Richter Gedeon Vegyeszet | Process for preparing novel octahydro-indolo/2,3-a/quinoline derivative and pharmaceutical comprising this compound |
| US4710504A (en) * | 1986-04-04 | 1987-12-01 | Merck & Co., Inc. | Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor |
| NZ216283A (en) | 1985-06-03 | 1989-10-27 | Merck & Co Inc | Hexahydro arylquinolizine derivatives and pharmaceutical compositions |
| AU582663B2 (en) | 1985-08-10 | 1989-04-06 | John Wyeth & Brother Limited | Sulphonamides |
| US4686226A (en) * | 1985-09-03 | 1987-08-11 | Merck & Co., Inc. | Substituted benzo[b]furo- and benzo[b]thieno quinolizines |
| US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
| BR9813381A (pt) | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
-
2003
- 2003-04-03 CA CA002480695A patent/CA2480695A1/en not_active Abandoned
- 2003-04-03 MX MXPA04009601A patent/MXPA04009601A/es not_active Application Discontinuation
- 2003-04-03 DE DE60316672T patent/DE60316672T2/de not_active Expired - Lifetime
- 2003-04-03 EA EA200401301A patent/EA008537B1/ru not_active IP Right Cessation
- 2003-04-03 AU AU2003216760A patent/AU2003216760A1/en not_active Abandoned
- 2003-04-03 AT AT03712185T patent/ATE374773T1/de not_active IP Right Cessation
- 2003-04-03 US US10/510,019 patent/US7592350B2/en not_active Expired - Fee Related
- 2003-04-03 NZ NZ535950A patent/NZ535950A/en unknown
- 2003-04-03 PL PL03372657A patent/PL372657A1/xx not_active Application Discontinuation
- 2003-04-03 WO PCT/FI2003/000255 patent/WO2003082866A1/en not_active Ceased
- 2003-04-03 HR HR20041026A patent/HRP20041026A2/xx not_active Application Discontinuation
- 2003-04-03 EP EP03712185A patent/EP1490361B1/en not_active Expired - Lifetime
- 2003-04-03 IL IL16420303A patent/IL164203A0/xx unknown
- 2003-04-03 BR BR0309028-0A patent/BR0309028A/pt not_active IP Right Cessation
- 2003-04-03 JP JP2003580331A patent/JP2005522468A/ja active Pending
- 2003-04-03 RS YU87204A patent/RS87204A/sr unknown
- 2003-04-03 HU HU0500201A patent/HUP0500201A2/hu unknown
- 2003-04-03 CN CNB038084716A patent/CN100372845C/zh not_active Expired - Fee Related
-
2004
- 2004-10-01 IS IS7482A patent/IS7482A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE374773T1 (de) | 2007-10-15 |
| EP1490361A1 (en) | 2004-12-29 |
| WO2003082866A1 (en) | 2003-10-09 |
| US7592350B2 (en) | 2009-09-22 |
| CN1646528A (zh) | 2005-07-27 |
| HUP0500201A2 (hu) | 2005-07-28 |
| BR0309028A (pt) | 2005-02-15 |
| NZ535950A (en) | 2007-11-30 |
| CA2480695A1 (en) | 2003-10-09 |
| RS87204A (sr) | 2006-10-27 |
| US20060094740A1 (en) | 2006-05-04 |
| CN100372845C (zh) | 2008-03-05 |
| HRP20041026A2 (en) | 2005-06-30 |
| AU2003216760A1 (en) | 2003-10-13 |
| HK1075660A1 (en) | 2005-12-23 |
| US20070293527A9 (en) | 2007-12-20 |
| EA200401301A1 (ru) | 2005-06-30 |
| JP2005522468A (ja) | 2005-07-28 |
| PL372657A1 (en) | 2005-07-25 |
| DE60316672T2 (de) | 2008-07-17 |
| IL164203A0 (en) | 2005-12-18 |
| DE60316672D1 (de) | 2007-11-15 |
| EA008537B1 (ru) | 2007-06-29 |
| EP1490361B1 (en) | 2007-10-03 |
| MXPA04009601A (es) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7482A (is) | Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf | |
| LTC2228064I2 (lt) | Farmacinė kompozicija, kurios sudėtyje yra glikopirolatas ir beta-2 adrenoceptorinis antagonistas | |
| TW200608972A (en) | Aryl-pyridine derivatives | |
| MXPA04006322A (es) | Derivados de 6-fluorobiciclo[3.1.0]hexano. | |
| ATE374765T1 (de) | Substituierte heterocyclische amide | |
| ATE306261T1 (de) | Antithrombosemittel | |
| DE69830504D1 (de) | Antithrombotische mitteln | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| TW200614983A (en) | 5-substituted-2-phenylamino benzamides as MEK inhibitors | |
| DE69931393D1 (de) | Antithrombotische amide | |
| WO2004096134A3 (en) | Substituted 1,4-diazepines and uses thereof | |
| WO2001064645A3 (en) | Derivatives of quinoline as alpha-2 antagonists | |
| WO2004048352A3 (en) | 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors | |
| TW200420545A (en) | 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | |
| WO2002085861A8 (en) | Imidazolidine compounds and their use as cxcr3 antagonists | |
| ATE402175T1 (de) | 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| ATE261941T1 (de) | Heterocyclische amide als inhibitoren von faktor xa | |
| TWI367882B (en) | Preparation and use of 2-substituted-5-oxo-3-pyrazolidinecarboxylates | |
| ATE308540T1 (de) | Antithrombosemittel | |
| EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
| NO20025323D0 (no) | Nye polysykliske indanylimidazoler med alfa2-adrenerg aktivitet | |
| DE69402703D1 (de) | 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND | |
| CA2309485A1 (en) | New 4-arylpiperidine derivatives for the treatment of pruritus | |
| EP1707560A4 (en) | HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE |